



Stefan Stevanovic

Contact

Stefan Stevanovic

Publications (10)

Marcu A, Walz J, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler M, Erhard F, Schlosser A, Kohlbacher O, Stevanovic S, Rammensee H, Kapolou K, Martin R, Hauri-Hohl M, Bichmann L, Kuchenbecker L, Kowalewski D, Freudenmann L, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Neidert M. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. *J Immunother Cancer* 2021; 9

Bilich T, Stevanovic S, Rammensee H, Neidert M, Schuhmacher J, Lübke M, Marcu A, Besemer B, Weisel K, Salih H, Roerden M, Walz S, Bauer J, Nelde A, Walz J. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. *Blood Cancer J* 2020; 10:24.

Bilich T, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper J, Klein R, Kohlbacher O, Kanz L, Rammensee H, Stevanovic S, Brümmendorf T, Schemionek M, Rieth J, Nelde A, Bichmann L, Roerden M, Salih H, Kowalewski D, Schuster H, Tsou C, Marcu A, Neidert M, Lübke M, Walz J. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. *Blood* 2018; 133:550–565.

Neidert M, Rammensee H, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Wolpert F, Walz J, Kowalewski D, Silginer M, Kapolou K, Backert L, Freudenmann L, Peper J, Marcu A, Wang S, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. *Acta Neuropathol* 2018; 135:923–938.

Backert L, Stevanovic S, Rammensee H, Weisel K, Kohlbacher O, Salih H, Kanz L, Niederwieser D, Vucinic V, Brümmendorf T, Schemionek M, Neidert M, Berlin C, Schuster H, Walz S, Kowalewski D, Walz J. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. *Oncotarget* 2017; 8:43915–43924.

Neidert M, Dietrich P, Herold-Mende C, Rammensee H, Honegger J, Melms A, Christ L, Trautwein N, Trautwein C, Schoor O, Stevanovic S. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. *J Neurooncol* 2012; 111:285–94.

Rückrich T, Driessen C, Reich M, Melms A, Beck A, Wiederanders B, Schilling K, Stevanovic S, Müller M, Cansier A, Brandenburg J, Kalbacher H. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. *Biol Chem* 2006; 387:1503–11.

Dengjel J, Rammensee H, Driessen C, Brock R, Kalbacher H, Brandenburg J, Altenberend F, Kreyberg K, Müller M, Kraus M, Reich M, Fischer R, Schoor O, Stevanovic S. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102:7922–7.

Burster T, Kalbacher H, Stevanovic S, Lehmann R, Melms A, Wiendl H, Schwarz G, Brandenburg J, Reich M, Lautwein A, Falk K, Rotzsche O, Marin-Esteban V, Tolosa E, Beck A, Driessen C. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes. *Journal of Immunology (Baltimore, Md. : 1950)* 2004; 172:5495–503.

Tolosa E, Melms A, Kurek R, Stevanovic S, Weber E, Schnorrer P, Driessen C, Lautwein A, Denzin L, Wienhold W, Yasuda Y, Li W, Bromme D. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. *The Journal of Clinical Investigation* 2003; 112:517–26.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch